The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
By Ann Mullally, MD
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of ima
...view more
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!
Author Information
By Ann Mullally, MD, Dana-Farber/Brigham and Women's Cancer Center
https://www.asia.elsevierhealth.com/the-treatment-of-myeloid-malignancies-with-kinase-inhibitors-an-issue-of-hematologyoncology-clinics-of-north-america-9780323532358.html295363The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9780323532358_7.jpg98.09108.99USDInStock/Clinics/Medicine & Surgery/Hematology/Medicine/Hematology/Clinics/Clinics/Medicine/Hematology/Japan Titles43887254431214505462250546665255041525991152631601418269243350884886536505455351451205259833This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more! This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!00add-to-cart97803235323582017ProfessionalBy Ann Mullally, MD20171Book152w x 229h (6.00" x 9.00")Elsevier0Jul 11, 2017IN STOCKBy <STRONG>Ann Mullally</STRONG>, MD, Dana-Farber/Brigham and Women's Cancer CenterClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
